Literature DB >> 11947906

Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage.

Junji Kobayashi1, Hiroshi Okamoto, Masako Otabe, Hideaki Bujo, Yasushi Saito.   

Abstract

We have previously reported a potent and specific cholesteryl ester transfer protein (CETP) inhibitor JTT-705 was a potentially anti-atherogenic compound (Nature 406 (2000) 203). In the present study, we investigated in vitro how this compound affects properties of high density lipoprotein (HDL) in Japanese white (JW) rabbits in terms of reverse cholesterol transport in J774 macrophages. Plasma HDL-cholesterol (C) level was significantly higher in the rabbits administered JTT-705 than in control rabbits on days 3 and 7. Both HDL(2) and HDL(3)-C levels were also significantly higher in JTT-705-administered rabbits than in control rabbits. During this period, plasma CETP activity was kept lower in JTT-705-administered rabbits than in controls. To determine how this compound affects the property of HDL particles, we investigated the C efflux induced by HDL from JTT-705-administered and control rabbits in J774 macrophages. Cholesterol ester (CE) concentration in J774 macrophages was reduced in proportion with increasing concentration of the added HDL to the culture media for J774 macrophages in both groups, suggesting that the HDL from JTT-705-administered rabbits was able to reduce CE concentration in J774 macrophages as efficiently as that from control rabbits. This result, together with the finding that the absolute HDL concentration increased in JW rabbits administered this CETP inhibitor, suggests that treatment with this new compound causes a beneficial effect on lipid metabolism in terms of anti-atherogenicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11947906     DOI: 10.1016/s0021-9150(01)00705-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.

Authors:  Ronald M Krauss; Kathleen Wojnooski; Joseph Orr; J Casey Geaney; Cathy Anne Pinto; Yang Liu; John A Wagner; Julie Mabalot Luk; Amy O Johnson-Levonas; Matt S Anderson; Hayes M Dansky
Journal:  J Lipid Res       Date:  2011-12-17       Impact factor: 5.922

Review 2.  New horizons for cholesterol ester transfer protein inhibitors.

Authors:  Gregory G Schwartz
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

Review 3.  On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.

Authors:  Douglas G Johns; Joseph Duffy; Timothy Fisher; Brian K Hubbard; Michael J Forrest
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 4.  Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.

Authors:  Alyse S Goldberg; Robert A Hegele
Journal:  Drug Des Devel Ther       Date:  2012-09-24       Impact factor: 4.162

5.  Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting.

Authors:  Tetsuro Miyazaki; Kazunori Shimada; Katsumi Miyauchi; Atsumi Kume; Kosei Tanimoto; Takashi Kiyanagi; Katsuhiko Sumiyoshi; Makoto Hiki; Hiroshi Mokuno; Shinya Okazaki; Hitoshi Sato; Takeshi Kurata; Hiroyuki Daida
Journal:  Lipids Health Dis       Date:  2010-10-25       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.